Research programme: T-cell therapies - TCR2 TherapeuticsAlternative Names: TCR fusion construct T-cell therapies - TCR2 Therapeutics; TRuC™ T-cells
Latest Information Update: 22 Dec 2016
At a glance
- Originator TCR2 Therapeutics
- Developer Ludwig-Maximilians-University; Massachusetts General Hospital; TCR2 Therapeutics; University of Freiburg
- Class Antineoplastics; T lymphocyte cell therapies
- Mechanism of Action Immunostimulants; T-cell receptor antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer